Indivior Pharmaceuticals (INDV) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.15
- Estimate
- $0.92
- Surprise
- +24.8%
- Revenue (period 2026-06-30)
- $343.0M
- Score at report (before → after)
- 6.8 → 6.9/10
Revenue source: xbrl.
How the report landed
Indivior Pharmaceuticals (INDV) beat the $0.92 estimate with adjusted EPS of $1.15 — a large 24.8% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.8/10) to Hold at 6.9/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates INDV Buy (Wait) at 6.4/10.
3 of the last 4 quarters beat the estimate; this quarter's +24.8% surprise compares with a +30.6% four-quarter average. Next scheduled report: 2026-10-29.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- News modifier +2: HOLD_IF_HOLDING → STRONG_BUY_WAIT
- Reward/Risk 1.4:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $36.38
- Entry target
- $35.12
- Price target
- $42.07
- Stop
- $32.66
- Upside to target
- +15.6%
- Reward-to-risk
- 1.4:1
The stock trades at 12.5× trailing but 7.7× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
INDV at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $4.10B
- P/E (fwd)
- 7.7
- P/E (ttm)
- 12.5
- 52-week range
- $24.74–$42.81
- Off 52-week high
- 15.0%
- RSI (14)
- 53
- Volume vs avg
- 0.17×
- Score today
- 6.4/10